Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

119
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
119
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

134
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
134
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

147
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
147
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

194
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
194
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

316
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
316
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

112
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
112

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Global Trends and Insights in Cervical Cancer Research: A Bibliometric Analysis from 2000 to 2024.

Reproduction & fertility·2026
Same author

Biofilm mediated arsenic migration and transformation in groundwater under the influence of dissolved organic matter.

Journal of hazardous materials·2026
Same author

Retrospective detail reconstruction network for mitigating shallow information loss in colorectal polyp segmentation.

Scientific reports·2026
Same author

Biological applications and future perspectives of bioactive compounds as pig feed additives.

Animal nutrition (Zhongguo xu mu shou yi xue hui)·2026
Same author

Does exercise rehabilitate the mind behind bars? The impact of physical activity on anxiety, depression, and stress in incarcerated individuals: A systematic review and multilevel meta-analysis.

Psychology of sport and exercise·2026
Same author

Solid-State Fermentation Using Mushrooms Enhances Wheat Bran Functionality and Whole-Wheat Bread Quality.

Plant foods for human nutrition (Dordrecht, Netherlands)·2026

Related Experiment Video

Updated: Jun 6, 2025

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
08:53

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

805

A Metal-Polyphenol-Based Antidepressant for Alleviating Colitis-Associated Mental Disorders.

Zihao Wang1, Zi-Xi Wang1, Ke-Fei Xu1

  • 1State Key Laboratory of Digital Medical Engineering, Jiangsu Key Laboratory for Biomaterials and Devices, School of Biological Science and Medical Engineering, Southeast University, Nanjing, 211189, P. R. China.

Advanced Materials (Deerfield Beach, Fla.)
|December 3, 2024
PubMed
Summary

A novel metal-polyphenol antidepressant, CSMTC, effectively treats depression in colitis mice by targeting the microbiota-gut-brain axis. This nanodrug restores gut health, reduces neuroinflammation, and improves mental well-being in inflammatory bowel disease models.

Keywords:
central nervous systemcolitisdepression‐like behaviormetal–polyphenol networkmicrobiota–gut–brain axis

More Related Videos

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

12.2K
Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression
07:58

Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression

Published on: February 24, 2023

454

Related Experiment Videos

Last Updated: Jun 6, 2025

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
08:53

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

805
Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

12.2K
Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression
07:58

Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression

Published on: February 24, 2023

454

Area of Science:

  • Nanomedicine
  • Neuroscience
  • Gastroenterology

Background:

  • Inflammatory bowel diseases (IBD) are linked to psychosocial issues like depression and anxiety.
  • Current antidepressants are often ineffective for IBD-related mental health problems due to gut-brain axis dysfunction.

Purpose of the Study:

  • To develop and evaluate a metal-polyphenol-based antidepressant (CSMTC) for treating mental disorders in experimental colitis.
  • To investigate CSMTC's mechanism of action via the microbiota-gut-brain axis.

Main Methods:

  • CSMTC, containing antioxidant enzymes and a tannic acid-cerium ion network, was administered orally to dextran sulfate sodium-induced colitis mice.
  • Evaluated effects on colonic redox balance, intestinal barrier, gut microbiota, blood-brain barrier integrity, and systemic immunity.
  • Assessed behavioral changes, neuroinflammation, neural plasticity, and neurotransmitter homeostasis in the hippocampus.

Main Results:

  • CSMTC restored colonic redox balance, strengthened the intestinal barrier, modulated gut microbiota, and maintained blood-brain barrier integrity.
  • CSMTC significantly alleviated depression-like behaviors in colitis mice.
  • Mechanism involved reducing neuroinflammation, enhancing hippocampal plasticity, and restoring neurotransmitter balance via the microbiota-gut-brain axis.

Conclusions:

  • CSMTC demonstrates therapeutic potential for IBD-associated mental disorders by modulating the microbiota-gut-brain axis.
  • This metal-polyphenol nanodrug offers a promising strategy for treating inflammation-related complications and mental health issues.